|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to our program of TKI dose reduction and withdrawal, all patients except 2 with diabetes were successfully continuing treatment.Overall, the present results demonstrated that renal function is negatively affected by long-term TKI treatment for RAI-refractory DTC.
|
31626129 |
2019 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations: BM</b> = bone metastases; <b>COX</b> = multivariate analyses; <b>DM</b> = distant metastases; <b>DSM</b> = disease-specific mortality; <b>DSS</b> = disease-specific survival; <b>DTC</b> = differentiated thyroid carcinoma; <b>ETE</b> = extrathyroidal extension; <b>LNM</b> = lymph node metastases; <b>OM</b> = overall mortality; <b>OS</b> = overall survival; <b>PTCFV</b> = papillary thyroid carcinoma; <b>RAI</b> = radioactive iodine; <b>SM</b> = spinal metastases; <b>SRE</b> = skeletal-related event; <b>txWBS</b> = whole-body scan after RAI therapy.
|
30657361 |
2019 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radioiodine treatment (RAI-T) of differentiated thyroid carcinoma (DTC) is important to avoid disease progression, in particular in pediatric patients.
|
30260898 |
2018 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CI = confidence interval; cStage = clinical stage; DTC = differentiated thyroid cancer; NCDB = National Cancer Data Base; OR = odds ratio; pStage = pathologic stage; RAI = radioactive iodine.
|
29144811 |
2018 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Retrospective study of 62 patients with metastatic RAI-R DTC to determine clinical outcomes with median follow-up from initial diagnosis of 11.1 years (8.38, 14.1) (range, 1.2-20 years).
|
30015659 |
2018 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, sora@Tf-HMSNs can significantly increase the effective drug concentration in cancer cells and thus enhance the anticancer effect, which are expected to be promising nanocarriers to deliver anticancer drugs for effective and safe therapy for RAI-refractory DTC.
|
30584304 |
2018 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even where multimodal treatment was ineffective, lenvatinib was suggested to be an alternative treatment option for RAI refractory recurrent DTC and patient could have a chance to be controlled successfully.
|
29954369 |
2018 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DTC = differentiated thyroid cancer; LASA = linear analog self-assessment; PR = partial response; QOL = quality of life; RAI = radioactive iodine; RAIR = RAI-resistant; RECIST = Response Evaluation Criteria In Solid Tumors; Tg = thyroglobulin; VEGFR = vascular endothelial growth factor receptor.
|
28816536 |
2017 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the last few years, several TKIs have been tested for the treatment of advanced, progressive and RAI-R thyroid cancers and some of them have been recently approved for use in clinical practice: sorafenib and lenvatinib for DTC and PDTC; vandetanib and cabozantinib for MTC.
|
28318881 |
2017 |
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study population (Group A) included all patients with low-risk differentiated thyroid cancer (DTC) who underwent total thyroidectomy and RAI between 1/1/2006 to 9/11/2015 with intrathyroidal T1-T2, Nx, N0 or N1a (≤5 nodes all measuring, when reported, <2 mm) that had anti-thyroglobulin antibodies.
|
28510122 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
According to our program of TKI dose reduction and withdrawal, all patients except 2 with diabetes were successfully continuing treatment.Overall, the present results demonstrated that renal function is negatively affected by long-term TKI treatment for RAI-refractory DTC.
|
31626129 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations: BM</b> = bone metastases; <b>COX</b> = multivariate analyses; <b>DM</b> = distant metastases; <b>DSM</b> = disease-specific mortality; <b>DSS</b> = disease-specific survival; <b>DTC</b> = differentiated thyroid carcinoma; <b>ETE</b> = extrathyroidal extension; <b>LNM</b> = lymph node metastases; <b>OM</b> = overall mortality; <b>OS</b> = overall survival; <b>PTCFV</b> = papillary thyroid carcinoma; <b>RAI</b> = radioactive iodine; <b>SM</b> = spinal metastases; <b>SRE</b> = skeletal-related event; <b>txWBS</b> = whole-body scan after RAI therapy.
|
30657361 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
CI = confidence interval; cStage = clinical stage; DTC = differentiated thyroid cancer; NCDB = National Cancer Data Base; OR = odds ratio; pStage = pathologic stage; RAI = radioactive iodine.
|
29144811 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
Overall, sora@Tf-HMSNs can significantly increase the effective drug concentration in cancer cells and thus enhance the anticancer effect, which are expected to be promising nanocarriers to deliver anticancer drugs for effective and safe therapy for RAI-refractory DTC.
|
30584304 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
Retrospective study of 62 patients with metastatic RAI-R DTC to determine clinical outcomes with median follow-up from initial diagnosis of 11.1 years (8.38, 14.1) (range, 1.2-20 years).
|
30015659 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
Even where multimodal treatment was ineffective, lenvatinib was suggested to be an alternative treatment option for RAI refractory recurrent DTC and patient could have a chance to be controlled successfully.
|
29954369 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
In the last few years, several TKIs have been tested for the treatment of advanced, progressive and RAI-R thyroid cancers and some of them have been recently approved for use in clinical practice: sorafenib and lenvatinib for DTC and PDTC; vandetanib and cabozantinib for MTC.
|
28318881 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
The study population (Group A) included all patients with low-risk differentiated thyroid cancer (DTC) who underwent total thyroidectomy and RAI between 1/1/2006 to 9/11/2015 with intrathyroidal T1-T2, Nx, N0 or N1a (≤5 nodes all measuring, when reported, <2 mm) that had anti-thyroglobulin antibodies.
|
28510122 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.090 |
Biomarker
|
disease |
BEFREE |
DTC = differentiated thyroid cancer; LASA = linear analog self-assessment; PR = partial response; QOL = quality of life; RAI = radioactive iodine; RAIR = RAI-resistant; RECIST = Response Evaluation Criteria In Solid Tumors; Tg = thyroglobulin; VEGFR = vascular endothelial growth factor receptor.
|
28816536 |
2017 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
<b>Abbreviations: BM</b> = bone metastases; <b>COX</b> = multivariate analyses; <b>DM</b> = distant metastases; <b>DSM</b> = disease-specific mortality; <b>DSS</b> = disease-specific survival; <b>DTC</b> = differentiated thyroid carcinoma; <b>ETE</b> = extrathyroidal extension; <b>LNM</b> = lymph node metastases; <b>OM</b> = overall mortality; <b>OS</b> = overall survival; <b>PTCFV</b> = papillary thyroid carcinoma; <b>RAI</b> = radioactive iodine; <b>SM</b> = spinal metastases; <b>SRE</b> = skeletal-related event; <b>txWBS</b> = whole-body scan after RAI therapy.
|
30657361 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
GeneticVariation
|
phenotype |
BEFREE |
Oncocytic NI-EFVPTC, when stringently selected for, lacks metastasis at presentation and follows an extremely indolent clinical course, even when treated conservatively with lobectomy alone without RAI therapy.
|
30689169 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Analysis of metastasis using a tumor xenograft mouse model further confirmed the role of Shc3 <i>in vivo</i> Taken together, our results indicate the importance of Shc3 in HCC progression and identify Shc3 as a novel biomarker and potential therapeutic target in HCC.<b>Significance:</b> Ectopic expression of Shc3 forms a complex with MVP/MEK/ERK to potentiate ERK activation and plays an important role in sorafinib resistance in HCC.<i></i>.
|
29330146 |
2018 |
|
Neoplasm Metastasis
|
0.060 |
GeneticVariation
|
phenotype |
BEFREE |
Papillary thyroid microcarcinoma, NI-EFV, when stringently selected for, lacks metastasis at presentation and follows an extremely indolent clinical course, even when treated conservatively without RAI therapy.
|
29204912 |
2018 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Derivative endpoints may include thyroid cancer incidence, the proportion of early-stage tumors detected, more treatable stage, the identification of small tumors (to maintain in observation), decrease in the number of people who develop metastatic disease, the increased chance of lesser extent surgery, and the application of minimally invasive approaches, as well as no need for lifelong thyroid replacement therapy, a consistent follow-up, low-dose or no RAI administration and risk factor assessments where case findings should be continuous.
|
28008561 |
2017 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Although controversy continues about the appropriate surgical management of PTC, total thyroidectomy is usually indicated given the frequent multicentricity and metastases of the disease, which in turn, necessitates adjuvant RAI and careful surveillance.
|
16882499 |
2006 |